<DOC>
	<DOCNO>NCT00943566</DOCNO>
	<brief_summary>The study hypothesis safety efficacy sufentanil follow transdermal application comparable sustain release morphine sulphate tablet patient chronic pain due cancer .</brief_summary>
	<brief_title>A Safety Efficacy Study Sufentanil Transdermal System Patients With Chronic Pain Due Cancer</brief_title>
	<detailed_description>The primary objective study compare consumption , milligram , rescue analgesia ( normal release morphine sulfate tablet ) administration sufentanil TDS sustain release morphine sulfate . The secondary efficacy objective study evaluate : - Pharmacokinetic data - Adverse event</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>1 . Male female patient age 18 75 diagnosis cancer ; 2 . If female , nonpregnant ( negative pregnancy test Visit 1 ) nonlactating ; 3 . If female , childbearing potential 4 . Documented history moderate severe chronic cancer pain require aroundtheclock therapy likely benefit WHO step III opioid analgesic duration study ; 5 . Has inform nature study provide write informed consent ; 6 . Is willing , able , competent complete entire study comply study instruction 1 . Patient pregnant lactate female ( serum pregnancy test conduct Screening Visit ) ; 2 . Any ongoing serious adverse event ( SAEs ) screen baseline ; 3 . Has schedule elective surgery invasive procedure period study participation ; 4 . Patients know intolerance opioid analgesic excipient Investigational Product ; 5 . Patients respiratory depression hypoxia and/or hypercapnia , sever chronic obstructive pulmonary disease , cor pulmonale , severe bronchial asthma , paralytic ileus , ( obstructive ) sleep apnea syndrome ; 6 . Evidence clinically significant cardiovascular , renal , hepatic psychiatric disease , determine medical history , clinical laboratory test , ECG result , physical examination , would place patient risk upon exposure study medication may confound analysis and/or interpretation result ; 7 . Abnormal aspartate aminotransferase ( AST ; SGOT ) , alanine aminotransferase ( ALT ; SGPT ) , alkaline phosphatase level ( &gt; 3 time upper level normal ) abnormal total bilirubin level ( &gt; 1.5 time upper level normal ) creatinine clearance &lt; 50 ml/min ( calculate use CockcroftGault formula ) ; 8 . Patients uncontrolled seizure ; 9 . Patients increase intracranial pressure ; 10 . Patients receive hypnotic central nervous system ( CNS ) depressant , opinion investigator , may pose risk additional CNS depression opioid medication ; 11 . Patients myxoedema , inadequately control hypothyroidism Addisons disease ; 12 . History alcohol and/or drug abuse ( positive urine drug screen Visit 1 ) within one year precede Screening Visit ; 13 . Active skin disease ; 14 . Patients suffer diarrhea and/or opioid withdrawal ; 15 . Known positive Hepatitis B C HIV status ; 16 . Has participate another clinical study drug device parallel &lt; 1 month study entry , previous participation study ; 17 . Is employee investigator study site direct involvement propose study study direction investigator study site , family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Morphine</keyword>
</DOC>